Biohaven Pharmaceutical Holding

BHVN

Held by 7 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

7 funds opened new positions. Short interest: 21.1% of float.

Share

BiotechnologyCEO: Vladimir CoricIPO: 2022Website ↗

Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.

Signal Score

5.5/10

7 funds opened new positions●●

No recent insider activity●●

No upcoming catalysts●●

Held by 7 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Fund Holdings

7 fund convergence

Driehaus Capital

Tang Capital ManagementHeld 7Q

Perceptive Advisors

Cormorant Asset ManagementHeld 7Q ↓

Rock Springs Capital

Redmile Group

Eventide Asset Management

Position history (shares)

Tang Capital Management

7Q

Perceptive Advisors

2Q

Cormorant Asset Management

7Q

Rock Springs Capital

3Q

Redmile Group

5Q

Eventide Asset Management

5Q

AI Signal

SIGNAL: High-conviction biotech crossover initiates BHVN position amid specialist fund convergence

Cormorant's $1.1M entry into Biohaven adds to a 7-fund specialist cluster (including Rock Springs, Perceptive, Redmile), suggesting conviction around near-term catalysts—likely pivotal readouts for ulixacaltide (CGRP antagonist for migraine) or rimegepant label expansion. Key risk: BHVN's cash position and burn rate should be monitored for dilution; confirm runway extends beyond Q2 2025 to validate the position thesis without near-term financing pressure.

Unlock full AI analysis — 14-day free trial

7 quarters

Position Trend

Nov 14, 2025

$2.3M

2 funds

Feb 13, 2026

$0

0 funds

Feb 17, 2026

$1.7M

2 funds

May 15, 2026

$0

0 funds

-100% total institutional value over 22 quarters

Short Interest

High short interestSI rising 3 periods (+18.2%)

Short Shares

24.87M

Change

+4.6%

Days to Cover

12.4

% of Float

21.1%

Settlement

Apr 30, 2026

Short interest over 6 periods

Catalysts

No catalysts tracked.

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Activist Filings

SC 13G/ARA Capital Management0.0%Feb 14, 2019

Conferences

View all

AANAttending

Chicago, ILApr 18, 2026

Position Details

Driehaus CapitalEXITMay 15, 2026

Start free trialfor share counts, dollar values & AI analysis

78 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

ASND1 fund IRD1 fund SLDB1 fund SYRE1 fund TNGX1 fund SION1 fund NBIX1 fund NRIX1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts:

Terms

Privacy

Disclaimer